Table 1.
Clinical trials evaluating the therapeutic efficacy of dexamethasone in COVID-19 patients (www.clinicaltrials.gov).
| S. No. | NCT No. | Title | Status | Phase | Population | Country |
|---|---|---|---|---|---|---|
| 1. | NCT04325061 | Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 (DEXA-COVID19) | Recruiting | Phase 4 | 200 individuals (18 years and older) | Spain |
| 2. | NCT04395105 | Dexamethasone for COVID-19 Related ARDS: a Multi-centre, Randomized Clinical Trial | Recruiting | Phase 3 | 284 individuals (18 years and older) | Argentina |
| 3. | NCT04347980 | Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19 (DHYSCO) | Recruiting | Phase 3 | 122 individuals (18 years and 80 years) | France |
| 4. | NCT04344730 | Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia (COVIDICUS) | Recruiting | Not Applicable | 550 individuals (18 years and older) | France |
| 5. | NCT04360876 | Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial | Not yet recruiting | Phase 2 | 90 individuals (18 years and older) | Not provided |
| 6. | NCT04327401 | COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III (CoDEX) | Active, not recruiting | Phase 3 | 350 individuals (18 years and older) | Brazil |
| 7. | NCT04445506 | Short Term Corticosteroids in SARS-CoV2 Patients | Completed | – | 50 individuals (18 years and older) | United States |
| 8. | NCT04476979 | Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 (TOCIDEX) | Not yet recruiting | Phase 2 | 120 individuals (18 years and older) | France |
| 9. | NCT04452565 | NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection (NATADEX) | Recruiting | Phase 2 and Phase 3 | 525 individuals (18 years and 80 years) | United States |
| 10. | NCT04381936 | Randomized Evaluation of COVID-19 Therapy (RECOVERY) | Recruiting | Phase 2 and Phase 3 | 15,000 individuals (Child, Adult, Older Adult) | United Kingdom |